8% Off
Ifomes400 mg/4 m
Beacon Pharmaceuticals PLC
৳174.80
Add to cart
Best PriceTk 171.00/400 mg vial
1
Medicine overview
Indications of Mes-D
Mes-D is an FDA-approved uroprotective (cytoprotective) agent indicated specifically for:
- Prophylaxis of ifosfamide-induced hemorrhagic cystitis - established, on-label use. Mes-D is given together with ifosfamide chemotherapy to reduce the incidence and severity of hemorrhagic cystitis.
- Prophylaxis of hemorrhagic cystitis induced by high-dose cyclophosphamide (e.g., in conditioning regimens prior to stem cell/bone marrow transplantation) - a guideline-supported, widely used practice, including some off-label/protocol-based dosing in this setting.
Mes-D is not indicated to reduce hematuria from other causes (such as thrombocytopenia or tumor invasion of the bladder) and does not treat or prevent any other toxicity of ifosfamide or cyclophosphamide, including myelosuppression or antitumor-unrelated adverse effects. Mes-D does not reduce the antitumor efficacy of ifosfamide or cyclophosphamide.
Composition
Each mL of Mesna injection typically contains Mesna 100 mg (e.g., 400 mg/4 mL per vial). Mesna is also available in some markets as oral tablets (e.g., 400 mg). Strength and pack size vary by manufacturer and formulation; always confirm the exact strength on the product label.
Description
Mes-D (sodium 2-mercaptoethanesulfonate) is a synthetic thiol (sulfhydryl) compound used as a uroprotective agent during chemotherapy with ifosfamide or high-dose cyclophosphamide. Mes-D itself has no antitumor activity and no effect on the systemic pharmacokinetics of the chemotherapy agents; its sole role is to chemically neutralize urotoxic metabolites within the urinary tract.
Mes-D is administered on a fixed schedule relative to each ifosfamide or cyclophosphamide dose, most commonly as intravenous bolus/infusion doses, sometimes combined with oral tablet doses.
Therapeutic Class
Uroprotective agent / chemoprotective (detoxifying) agent used in cancer chemotherapy; thiol compound.
Pharmacology
Mesna works by a direct chemical detoxification mechanism rather than a receptor-based pharmacologic action. After intravenous or oral administration, Mesna is rapidly oxidized in the plasma to its inactive disulfide metabolite (dimesna). Dimesna is then reduced back to free Mesna in the kidney and excreted into the urine, where free Mesna reaches high local concentrations.
Within the urinary tract, the free thiol group of Mesna binds covalently to and inactivates acrolein and other urotoxic metabolites of ifosfamide and cyclophosphamide, preventing them from damaging the bladder urothelium and thereby preventing hemorrhagic cystitis. Mesna does not cross into most other body tissues in significant amounts and does not interfere with the antineoplastic activity of ifosfamide or cyclophosphamide. Plasma half-life of free Mesna is short (about 1.5 hours), which is why repeated or combined IV/oral dosing is required to maintain adequate urinary concentrations throughout the period of urotoxic metabolite excretion.
Dosage & Administration of Mes-D
Mes-D dosing is calculated as a percentage of the ifosfamide or cyclophosphamide dose (by body surface area) and must be given on a strict schedule relative to the chemotherapy infusion. Exact regimens vary by protocol; the following reflects commonly used, label-based schedules for adults.
| Regimen | Mes-D dose/timing |
|---|---|
| IV bolus regimen (with ifosfamide) | Mes-D 20% of the ifosfamide dose given IV at the time of ifosfamide administration (hour 0), then repeated at 4 and 8 hours after each ifosfamide dose (total Mes-D dose = 60% of ifosfamide dose per cycle day). |
| IV + oral regimen (with ifosfamide) | Mes-D 20% of ifosfamide dose IV at hour 0, then 40% of the ifosfamide dose given orally at 2 and 6 hours after each ifosfamide dose (total Mes-D dose = 100% of ifosfamide dose). |
| High-dose cyclophosphamide (transplant conditioning) | Continuous infusion or intermittent bolus dosing of Mes-D, typically 60-160% of the cyclophosphamide dose in divided doses, per institutional/transplant protocol. |
Administration: Mes-D IV injection should be diluted in compatible IV fluids (e.g., 5% dextrose, normal saline, or Ringer's lactate) to a final concentration around 20 mg/mL and used within 24 hours of dilution. It can be given as a slow IV bolus or short infusion. Oral Mes-D tablets should be taken with a liquid, with or without food; if vomiting occurs within 2 hours of an oral dose, the dose should be repeated or switched to the IV route, as directed by the treating physician.
Maintain generous fluid intake/hydration before, during, and after chemotherapy, and monitor urine for blood (hematuria) with each cycle, even when Mes-D is given as prescribed. Always follow the exact dose, route, and schedule prescribed by the oncology team; do not adjust Mes-D timing independently, as inadequate Mes-D dosing or mistimed doses increase the risk of hemorrhagic cystitis. See Use in Special Populations for renal impairment considerations.
Administration of Mes-D
Mes-D is given intravenously (slow bolus injection or short infusion, diluted in compatible IV fluid) and/or orally (tablets taken with liquid). Timing relative to the ifosfamide/cyclophosphamide infusion is critical and must follow the prescribed protocol exactly; do not delay, skip, or self-adjust doses.
Interaction of Mes-D
Mes-D has not been subjected to formal clinical drug-interaction studies, but the following points are clinically important:
- Physical/chemical incompatibility: Mes-D should not be mixed in the same IV solution/syringe as cisplatin, carboplatin, nitrogen mustard, or epirubicin, as it can chemically inactivate these agents.
- Laboratory test interference: Mes-D can cause false-positive results for urinary ketones on dipstick testing and may falsely lower measured creatine phosphokinase (CPK) levels; interpret such lab results with this in mind during Mes-D therapy.
- Other nephrotoxic or bladder-irritant drugs: use with caution and close monitoring, since Mes-D only protects against the specific urotoxicity of ifosfamide/cyclophosphamide, not against other causes of urothelial or renal injury.
Contraindications
Mesna is contraindicated in patients with known hypersensitivity to Mesna or to other thiol (sulfhydryl) compounds. There are no other well-established absolute contraindications to Mesna itself; other cautions (e.g., benzyl alcohol content in some formulations) are addressed under Precautions and Warnings and Use in Special Populations rather than as absolute contraindications.
Side Effects of Mes-D
Adverse effects reported with Mes-D can be difficult to distinguish from those of the concurrent ifosfamide/cyclophosphamide chemotherapy, but commonly reported reactions (more than 10% of patients) include:
- Nausea and vomiting
- Diarrhea and constipation
- Fatigue, fever, and loss of appetite (anorexia)
- Headache
- Low blood counts (leukopenia, thrombocytopenia, anemia) - largely attributable to the co-administered chemotherapy
Less common but important reactions include allergic-type hypersensitivity reactions (rash, urticaria, pruritus, flushing, and rarely anaphylaxis), and rare severe skin reactions (Stevens-Johnson syndrome/toxic epidermal necrolysis) have been reported. Seek prompt medical attention for any rash, swelling of the face/lips/tongue, difficulty breathing, or skin blistering during Mes-D therapy.
Pregnancy & Lactation
Mes-D is always administered together with ifosfamide or high-dose cyclophosphamide, both of which can cause fetal harm; Mes-D itself has limited independent reproductive safety data. Mes-D should be used in pregnancy only if the treating oncology team determines that the potential benefit of the chemotherapy regimen justifies the potential risk to the fetus, and only under close specialist supervision; women of childbearing potential should use effective contraception during and for a period after treatment, as advised by their physician.
Breastfeeding is not recommended during treatment with Mes-D/ifosfamide or cyclophosphamide and for at least one week after the last dose, due to potential exposure of the infant through breast milk. Consult a physician before breastfeeding after completing therapy.
Precautions & Warnings
Mes-D requires several important precautions:
- Hypersensitivity reactions: Anaphylactic and other hypersensitivity reactions can occur with Mes-D; monitor patients, especially with repeated cycles, and have supportive treatment available.
- Does not prevent other toxicities: Mes-D only reduces urotoxicity of ifosfamide/cyclophosphamide; it does not reduce myelosuppression, nausea, or other systemic toxicities of these chemotherapy agents, and does not reduce their antitumor effect.
- Strict timing required: The protective effect of Mes-D depends on precise, on-schedule dosing relative to the chemotherapy infusion. Missed, delayed, or reduced doses increase the risk of hemorrhagic cystitis.
- Adequate hydration and urine monitoring: Maintain generous fluid intake and monitor urine for hematuria throughout each treatment cycle even while receiving Mes-D, since breakthrough hemorrhagic cystitis can still occur.
- Benzyl alcohol (in some injectable formulations): avoid in premature and low-birth-weight infants (see Use in Special Populations).
- Laboratory interference: can cause false-positive urine ketone tests and falsely low CPK results (see Interactions).
Overdose Effects of Mes-D
Limited data exist on Mes-D overdose; expected effects would be an extension of known adverse effects such as nausea, vomiting, diarrhea, hypotension, or allergic-type reactions. There is no specific antidote for Mes-D overdose. If an overdose of Mes-D is suspected, seek immediate medical attention or contact emergency services/a poison control center; management is supportive and symptomatic, guided by a physician.
Storage Conditions
Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Diluted Mes-D IV solutions should be used within the timeframe specified by the manufacturer (commonly within 24 hours of dilution) and any unused diluted solution should be discarded. Do not use if the solution is discolored or contains particles.
Use In Special Populations
Renal impairment: Patients with reduced renal function may have altered clearance of both Mes-D and the co-administered chemotherapy; dosing and monitoring should be individualized by the oncology team, with close attention to urine output and hematuria.
Hepatic impairment: No well-established dose adjustment is defined for Mes-D itself; use with the standard caution applied to the concurrent chemotherapy regimen.
Elderly: No Mes-D-specific dose adjustment is established; use with the general caution and monitoring applied to the chemotherapy regimen, considering age-related decline in renal function.
Pediatric use: Mes-D is used in children receiving ifosfamide or high-dose cyclophosphamide, with doses calculated by body surface area similarly to adults; safety and efficacy in this setting are supported by pediatric oncology experience, though formal pediatric labeling is limited. Mes-D injection formulations containing benzyl alcohol should be avoided in premature neonates and low-birth-weight infants because of the risk of benzyl alcohol toxicity ('gasping syndrome').
Duration Of Treatment
Mes-D is given only for the duration of, and immediately surrounding, each dose/cycle of ifosfamide or high-dose cyclophosphamide chemotherapy - it is not a standalone, continuous, or chronic therapy. The number of Mes-D doses per cycle and the number of cycles are determined by the overall chemotherapy protocol prescribed by the oncologist.
Reconstitution
Mes-D injection is supplied as a ready-to-use aqueous solution in most presentations and does not require reconstitution from a lyophilized powder; however, it must be diluted in a compatible IV fluid (such as 5% dextrose, normal saline, or Ringer's lactate) to the concentration specified on the product label before intravenous administration, and used within the stated timeframe after dilution.
Drug Classes
Uroprotective/chemoprotective agent; thiol (sulfhydryl) compound; detoxifying agent used as adjunct to chemotherapy.
Mode Of Action
Mesna is rapidly converted after administration into free thiol Mesna, which is excreted in high concentration into the urine. There, the sulfhydryl (-SH) group of Mesna reacts chemically with and inactivates acrolein and other urotoxic metabolites generated from ifosfamide/cyclophosphamide metabolism, preventing these metabolites from damaging the bladder lining and thereby preventing hemorrhagic cystitis, without altering the antitumor activity of the chemotherapy.
Pediatric Uses
Mes-D is used in pediatric patients receiving ifosfamide or high-dose cyclophosphamide chemotherapy, dosed by body surface area using schedules analogous to adult regimens, under pediatric oncology supervision. Injectable Mes-D products containing benzyl alcohol as a preservative must be avoided in premature neonates and low-birth-weight infants due to the risk of a potentially fatal 'gasping syndrome'; benzyl-alcohol-free formulations should be used in this age group when required. Safety and efficacy of specific dosing schedules in very young infants outside the neonatal risk group should be individualized by the treating pediatric oncologist.
Frequently Asked Questions
Q: What is Mes-D 400 mg/4 ml IV Injection used for?
A: Mes-D 400 mg/4 ml IV Injection is used to help prevent hemorrhagic cystitis (bladder irritation and bleeding) caused by certain chemotherapy drugs, specifically ifosfamide and high-dose cyclophosphamide. Mes-D 400 mg/4 ml IV Injection does not treat cancer itself and is always given together with, not instead of, chemotherapy.
Q: Does Mes-D 400 mg/4 ml IV Injection reduce how well my chemotherapy works?
A: No. Mes-D 400 mg/4 ml IV Injection only neutralizes a toxic byproduct in the urinary tract and does not reduce the antitumor effectiveness of ifosfamide or cyclophosphamide, nor does it protect against their other side effects such as low blood counts or nausea.
Q: Why is the timing of Mes-D 400 mg/4 ml IV Injection doses so important?
A: Mes-D 400 mg/4 ml IV Injection only protects the bladder while it is present in the urine at adequate concentrations. If doses of Mes-D 400 mg/4 ml IV Injection are missed, delayed, or reduced, the risk of hemorrhagic cystitis increases significantly, so it is essential to take or receive every dose of Mes-D 400 mg/4 ml IV Injection exactly on the schedule your oncology team prescribes.
Q: What side effects should I watch for with Mes-D 400 mg/4 ml IV Injection?
A: Common side effects of Mes-D 400 mg/4 ml IV Injection include nausea, vomiting, diarrhea, fatigue, and mild allergic-type reactions such as rash. Seek immediate medical attention for signs of a severe allergic reaction (facial or throat swelling, difficulty breathing) or severe skin blistering/peeling, as these are rare but serious reactions that have been reported with Mes-D 400 mg/4 ml IV Injection.
Q: Can Mes-D 400 mg/4 ml IV Injection be used during pregnancy or breastfeeding?
A: Mes-D 400 mg/4 ml IV Injection is given together with chemotherapy drugs that can harm a developing fetus, so it should be used in pregnancy only if your oncology team determines the benefit outweighs the risk, under close specialist supervision. Breastfeeding should be avoided during treatment with Mes-D 400 mg/4 ml IV Injection and for at least one week after the last dose; ask your physician before resuming breastfeeding.
Q: What should I do if I miss a dose or vomit after an oral Mes-D 400 mg/4 ml IV Injection tablet?
A: If you vomit within about 2 hours of taking an oral Mes-D 400 mg/4 ml IV Injection dose, or think you have missed a dose, contact your oncology team immediately rather than deciding on your own - the missed dose may need to be repeated or given by the intravenous route to maintain protection against hemorrhagic cystitis.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.
